News FDA warns of genital gangrene risk with diabetes drug class The US regulator released an official risk warning of a rare genital infection identified in 12 patients, including one fatality, after using SGLT2 class drugs for type 2 diabetes.
Views & Analysis SGLT2 inhibitors: an emerging option for cardiologists? With studies showing potential for SGLT2 inhibitors in heart failure, a study of HCP online conversations reveals cardiologists are still cautious.
UK & Europe AZ’s diabetes combination Qtern approved in Europe The European Commission has granted marketing approval to a new combination pill from AstraZeneca to treat type 2 diabetes.
Oncology LSX2026: Addressing adult eye cancer, with Roi Raz Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
